“Procalcitonin in respiratory disease: use as a biomarker for diagnosis and guiding antibiotic therapy” Breathe 2019; 15: 296–304.

Source: Breathe, 15 (4) e152; 10.1183/20734735.5258-2019
Journal Issue: December
Disease area: Respiratory infections

Full text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
“Procalcitonin in respiratory disease: use as a biomarker for diagnosis and guiding antibiotic therapy” Breathe 2019; 15: 296–304.. Breathe, 15 (4) e152; 10.1183/20734735.5258-2019

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.

Related content which might interest you:
Procalcitonin in respiratory disease: use as a biomarker for diagnosis and guiding antibiotic therapy
Source: Breathe, 15 (4) 296; 10.1183/20734735.0258-2019
Year: 2019

Could procalcitonin (PCT) be a marker of effectiveness of antibiotic treatment (ABT) in pregnant with not severe community-acquired pneumonia (CAP)?
Source: International Congress 2015 – Healthcare organisation and appropriateness in lung disorders
Year: 2015

The practice of empiric antibiotic therapy in patients with coronavirus disease 2019 (COVID-19).
Source: Virtual Congress 2021 – COVID – 19: treatments and predictive factors
Year: 2021

Procalcitonin to guide antibiotic administration in COPD exacerbations: a meta-analysis
Source: Eur Respir Rev 2017; 26: 160073
Year: 2017

Can we use a biomarker to guide antibiotic treatment in severe COPD exacerbations?
Source: Breathe, 15 (4) 353; 10.1183/20734735.0257-2019
Year: 2019

Indication for antibiotic therapy in AECB: anthonisen‘s criteria versus procalcitonin
Source: Eur Respir J 2004; 24: Suppl. 48, 50s
Year: 2004

Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomised study
Source: Eur Respir J 2009; 34: 1364-1375
Year: 2009

C-reactive protein (C-RP) in patients with chronic heart failure (CHF) and community-acquired pneumonia (CAP): usefulness to guide antibiotic prescription
Source: International Congress 2018 – Predicting the future: biomarkers of respiratory infection
Year: 2018

Changes in empirical initial antibiotic therapy in community-acquired pneumonia: assessment of clinical failure versus discordant therapy
Source: Eur Respir J 2006; 28: Suppl. 50, 736s
Year: 2006

Pneumonia: diagnosis, treatment and prevention
Source: International Congress 2018 – State of the art session: Respiratory infections
Year: 2018

Point-of-care procalcitonin test to reduce antibiotics in COPD exacerbation: A quasi-randomised control trial
Source: International Congress 2015 – Infection in COPD: different aspects of the host/pathogen balance
Year: 2015

Efficacy of using special software “Optimization of medication choice for treatment of patient with comorbidity” (SS) for management of patients with community-acquired pneumonia (CAP) and cardiovascular disease
Source: International Congress 2019 – M-health/e-health I
Year: 2019

Can procalcitonin testing reduce antibiotic prescribing for respiratory infections?
Source: Annual Congress 2006 - Inflammation markers in community-acquired pneumonia
Year: 2006

Individual monitoring of procalcitonin and C-reactive protein levels as a criterion for cancel of antibiotic therapy in patients with severe community-acquired pneumonia
Source: Annual Congress 2013 –Biomarkers, diagnosis and outcome of respiratory infections
Year: 2013

Late Breaking Abstract - Severe pneumonia patients may could not benefit from antibiotic combination therapy and non-invasive ventilation(NIV), despite the advanced mode
Source: International Congress 2018 – Non-invasive ventilation for acute respiratory failure
Year: 2018

Should we change our antibiotic strategy in AECOPD or CAP+COPD patients?
Source: International Congress 2015 – Differentiating COPD exacerbations from pneumonia in COPD patients
Year: 2015

Sputum induction for assessment of biomarkers in early development of new drugs for respiratory disease in a proof of concept setting
Source: International Congress 2016 – Airway biomarkers
Year: 2016

Biomarkers in respiratory tract infections: diagnostic guides to antibiotic prescription, prognostic markers and mediators
Source: Eur Respir J 2007; 30: 556-573
Year: 2007

Improved diagnostics and diagnostic approaches: The role in the fight to emerging infectious diseases (EID) and antimicrobial resistance (AMR)
Source: Postgraduate course 2021: PG7 - Postgraduate course : Emerging infectious diseases and antimicrobial resistance: diagnostics, treatments, vaccines and other preventive and/or therapeutic interventions
Year: 2021

Efficacy of early COPD diagnosis and intervention system
Source: International Congress 2014 – Physical activity, exercise and physiotherapy in patients with COPD
Year: 2014